Finerenone is a non-steroidal mineralocorticoid receptor antagonist (MRA) used for the treatment of chronic kidney disease (CKD) associated with type 2 diabetes mellitus. It selectively blocks overactivation of the mineralocorticoid receptor, reducing inflammation and fibrosis in the kidneys and heart without the hormonal side effects typically associated with steroidal MRAs like spironolactone or eplerenone.
Finerenone is marketed under the brand name Kerendia® and is administered orally.
Therapeutic indications include:
• Chronic kidney disease (CKD) in adults with type 2 diabetes
• Slowing the progression of renal dysfunction
• Reducing the risk of cardiovascular events in CKD patients
Parent: Finerenone
Parent: Finerenone
Parent: Finerenone
Parent: Finerenone
Parent: Finerenone
Impurities in finerenone primarily arise from its multi-step synthetic route, which involves heterocyclic ring construction, chiral center introduction, and amide coupling. Finerenone contains a dihydropyridine-based non-steroidal core, and impurity control is governed by ICH Q3A/B for organic impurities, ICH M7 for potential genotoxic impurities, and ICH Q3D for elemental impurities.
Process-Related Impurities
• Unreacted starting materials like substituted pyridines or carboxylic acid derivatives
• Intermediate compounds from partial or failed coupling steps
• Regioisomeric and stereoisomeric impurities (important due to chirality)
• Residual solvents such as acetonitrile, DMF, or ethyl acetate
• Coupling reagent by-products (e.g., carbodiimide-related residues)
Degradation Impurities
• Hydrolytic degradation of the amide bond
• Oxidation of heterocyclic or aromatic components
• Isomerization or rearrangement of the dihydropyridine ring
• Photodegradation under light exposure
Elemental Impurities
• Trace metals such as palladium, iron, or copper used in synthesis
• Controlled under ICH Q3D limits for oral drug products
Analytical Techniques for Impurity Detection
Finerenone is used to treat chronic kidney disease in adults with type 2 diabetes, helping to slow disease progression and reduce cardiovascular risk.
It blocks the mineralocorticoid receptor, reducing inflammation and fibrosis in the kidneys and heart without hormonal side effects.
Yes. Finerenone is non-steroidal and more selective for the mineralocorticoid receptor, with fewer hormonal side effects and improved tolerability.
Store at 20–25°C in a dry, tightly closed container, protected from light and moisture.
